Monogram Orthopaedics, Inc. (NASDAQ: MGRM) witnessed a remarkable surge of 27.67% in its stock value, concluding the latest trading session at $3.92. This ascent in Monogram’s stock was precipitated by a momentous achievement in product delivery.
Monogram (MGRM) announced the successful delivery of its inaugural surgical robot to one of the world’s largest distributors of global robotics. The act of delivering the first robot, coupled with the realization of initial commercial revenues, not only affirms the technological prowess of Monogram but also signifies a pivotal milestone in its strategic trajectory.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The operational efficiency of MGRM’s system has been outstanding, prompting the company to shift its focus towards observing how its robot performs and scales in real-world applications. The overarching objective of Monogram is to elevate the standard of care in orthopedic joint replacement surgery through cutting-edge, next-generation active surgical robotics.
In its first target market—comprising approximately 88% of manually conducted knee replacement surgeries—the mBôs robot by MGRM endeavors to amalgamate safety, user-friendly operation, cost efficiency, innovative implant design, extensive clinical functionality, and speed, thereby catalyzing the impending surge in robotic adoption within orthopedics.
This year, Monogram successfully concluded the Development Phase and initiated the Verification Phase for its upcoming autonomous surgical robotic system, marking a pivotal juncture in the company’s path to commercialization. Throughout the Verification phase, MGRM subjected its autonomous surgical robotics and associated software.
With the Verification phase completed, MGTM anticipates transitioning into the Validation phase to ascertain that the technology aligns with the needs and expectations of end-users and customers.
This phase will comprehensively evaluate the product’s usability and appropriateness in real-world scenarios, encompassing simulated surgeries on cadavers by surgeons and assessments of iatrogenic injury and general product performance.
Monogram has substantiated its commitment to innovation by filing over 20 patent applications encompassing various facets of autonomous robotic execution, custom implants, and novel tracking methods.
Its aspiration is to be the inaugural autonomous system on the market employing a robot-mounted sagittal saw. Notably, in March 2023, Monogram achieved a historic milestone with the successful execution of the first fully remote simulated robotic surgery.
